

ABSTRACT

Lysostaphin is demonstrated to be a powerful anti-staphylococcal agent suitable for parenteral administration to mammals including humans. Low dosages, on the order of 0.5 - 45 mg/kg/day are sufficient to eradicate most staphylococcal infections. Lysostaphin is also effective against bacteria of this type which have developed resistance to conventional antibiotics such as penicillins and vancomycin. Lysostaphin analogues, such as variants and related enzymes, show similar activity.

09120030 0724 98
86 F220 02002150